GTMB 7 - Gene Therapy & Molecular Biology

More documents

Recommendations

Info

Latchman: Protective effect of heat shock proteinsmolecular chaperones and negative regulators. Genes Dev12, 3788-3796.Morris SD, Cumming DVE, Latchman DS and Yellon DS,(1996) Specific induction of the 70kDa heat stress proteinsby the tyrosine kinase inhibitor herbimycin-A protects ratneonatal cardiomyocytes A new pharmacological route tostress protein expression. J Clin Invest 97, 706-712.Nishizawa J Nakai A, Matsuda K, Komeda M, Ban, T andNagata K, (1999) Reactive oxygen species play an importantrole in the activation of heat shock factor 1 in ischemicreperfusedheart. Circulation 99, 934-941.Norton, P. M. and Latchman DS (1989) Levels of the 90kd heatshock protein and resistance to glucocorticoid mediated cellkilling in a range of human and murine lymphocyte celllines. Genes Dev 33, 149-154..Nowak, T. S. J, (1985) Synthesis of a stress protein followingtransient ischaemia in the gerbil. J Neurochem 45, 1635-1641.Parsell DA and Lindquist S, (1993) The functional of heat-shockproteins in stress tolerance, Degradation and reactivation ofdamaged proteins. Annu Rev Biochem 27, 437-496.Pennica D, King, KL, Shaw, K. J, Luis, E, Rullamas J, Luoh SM,Darbonne WC, Knutzon DS, Yen R, Chien KR, Baker JBand Wood WI, (1995) Expression cloning of cardiotrophin 1a cytokine that induces cardiac myocyte hypertrophy.Proc.Natl.Acad.Sci.USA, 92, 1142-1146.Plesset J, Palm C, and McLaughlin CS, (1982) Induction of heatshock proteins and thermotolerance by ethanol inSaccharomyces cerevisiae. Biochem Biophys Res Commun108, 1340-1345.Plumier JCL, Krueger, AM, Currie RW, Kontoyiannis G, KolliasG and Pagoulatos GN, (1997) Transgenic mice expressingthe human inducible hsp70 have hippocampal neuronsresistant to ischemic injury. Cell Stress Chaperones 2, 162-167.Plumier JCL, Ross, B. M Currie RW Angelidis C. E, Kazlaris H,Kollias G and Pagoulatos GN, (1995) Transgenic miceexpressing the human heat shock protein 70 have improvedpostischemic myocardial recovery. J Clin Invest 95, 1854-1860.Polla BS, (1988) A role for heat shock proteins in inflammation?Immunol Today 9, 134-137.Radford NB, Fina M, Benjamin IJ, Moreadith RW, Graves KH,Zhao, P, Gavva S, Wiethoff A, Sherry AD, Malloy C. R andWilliams RS, (1996) Cardioprotective effects of 70kDa heatshock protein in transgenic mice. Proc.Natl.Acad.Sci.USA93, 2339-2342.Rajdev S, Hara K, Kokubo Y, Mestril R, Dillmann W, WeinsteinPR and Sharp FR, (2000) Mice overexpressing rat heat shockprotein 70 are protected against cerebral infarction. AnnNeurol 47, 782-791.Rebbe NF, Ware J, Bertina RM, Modrich P and Stafford DW,(1987) Nucleotide sequence of a cDNA for a member of the90kDa heat shock protein family. Gene 53, 235-245.Ripley, B. J. M, Stephanou A, Isenberg DA and Latchman DS(1999) Interleukin-10 activates heat shock protein 90β geneexpression. Immunology 97, 226-231.Ritossa, F, (1962) A new puffing pattern induced andtemperature shock and DNP in Drosophila. Experientia 18,571-573.Robertson JD, Datta K, Biswal SS and Kehrer JP, (1999) Heatshockprotein 70 antisense oligomers enhance proteasomeinhibitor-induced apoptosis. Biochem J 344, 477-485.Rordorf G, Koroshetz, W. J and Bonventre JV, (1991) Heatshock protects cultured neurons from glutamate toxicity.Neuron 7, 1043-1052.Stephanou A and Latchman DS Transcriptional regulation of theheat shock protein genes by STAT family transcriptionfactors. Gene Expr 1999, 7, 311-319.Stephanou A Amin V, Isenberg DA Akira S, Kishimoto, T andLatchman DS (1997) Interleukin-6 activates heat shockprotein 90β gene expression. Biochem J 321, 103-106.Stephanou A, Brar B, Heads R, Knight RD, Marber MS, Pennica,D and Latchman DS (1998) Cardiotrophin-1 induces heatshock protein accumulation in cultured cardiac cells andprotects them from stressful stimuli. J Mol Cell Cardiol 30,849-855.Suzuki K, Sawa, Y, Kaneda, Y, Ichikawa H, Shirakura, R andMatsuda H, (1997) In vivo gene transfection with heat shockprotein 70 enhances myocardial tolerance to ischemiareperfusioninjury in rat. J Clin Invest 99, 1645-1650.Suzuki K, Sawa Y, Kaneda Y, Ichikawa H, Shirakura R andMatsuda H, (1998) Overexpressed heat shock protein 70attenuates hypoxic injury in coronary endothelial cells. JMol Cell Cardiol 30, 1129-1136.Trost SU, Omens JH, Karlon, W. J, Meyer M, Mestril R CovellJW and Dillmann, W. H, (1998) Protection againstmyocardial dysfunction after a brief ischemic period intransgenic mice expressing inducible heat shock protein 70. JClin Invest 101, 855-862.Uney JB, Kew C. N. N, Staley K, Tyers, P and Sofroniew MV,(1993) Transfection mediated expression of human hsp70iprotects rat dorsal root ganglion neurones and glia from heatshock. FEBS Letters 334, 313-317.Vigh L, Literati, P. N, Horvath I, Torok Z, Balogh G, Glatz A,Kovacs E, Boros I, Ferdinandy P, Farkas B, Jaszlits L,Jednakovits A, Koranyi, L and Maresca B, (1997)Bimoclomol A nontoxiC hydroxylamine derivative withstress protein-inducing activity and cytoprotective effects.Nature Med 3, 1150-1154.Wagstaff MJD, Collaco-Moraes Y, Smith J, de Belleroche J,Coffin RS and Latchman DS (1999) Protection of neuronalcells from apoptosis by hsp27 delivered with a herpessimplex virus-based vector. J Biol Chem 274, 5061-5069.Wagstaff MJD, Smith J, Collaco-Moraes Y, de Belleroche JS,Coffin RS and Latchman DS (1998) Delivery of aconstitutively active form of the heat shock factor using avirus vector protects neuronal cells from thermal orischaemic stress but not from apoptosis. Eur J Neurosci 10,3343-3350.Wyatt S, Mailhos C and Latchman DS (1996) Trigeminalganglion neurons are protected by the heat shock proteinshsp70 and hsp90 from thermal stress but not fromprogrammed cell death following NGF withdrawal. MolBrain Res 39, 52-56.Yellon DM. and Latchman DS (1992) Stress proteins andmyocardial protection. J Mol Cell Cardiol 24, 113-124.Yellon DM, Pasini E Cargnoni A, Marber MS, Latchman DS andFerrari R, (1992) The protective role of heat stress in theischaemic and reperfused rabbit myocardium. J Mol CellCardiol 24, 895-907.254
Gene Therapy and Molecular Biology Vol 7, page 255Lung cancer gene therapyReview ArticleGene Ther Mol Biol Vol 7, 255-272, 2003Kexia Cai 1 , Mai Har Sham 2 , Paul Tam 3 , Wah Kit Lam 4 and Ruian Xu 1*1 Gene Therapy Laboratory, IMB, 2 Department of Biochemistry and 3 Department of Surgery and 4 Department of Medicine,The University of Hong Kong, Hong Kong__________________________________________________________________________________*Correspondence: RA Xu, Gene Therapy Laboratory, IMB, The University of Hong Kong, Hong Kong; Tel: (852) 22990757; Fax:(852) 2817 9488; e-mail: rxua@hkucc.hku.hkKey words: lung cancer, gene therapy, tumor suppressor genes, growth factor pathway targets, suicide gene therapy, angiogenesis,immunotherapyAbbreviations: small cell lung cancer (SCLC); non-small cell lung cancer (NSCLC); intratumoral injection of Ad-p53 (INGN 201);murine double minute-2 (MDM2); cisplatin (CDDP); active metabolite of irinotecan (CPT-11); O(6)-methylguanine-DNAmethyltransferase (MGMT); retinoblastoma (RB); fragile histidine triad (FHIT); tumor necrosis factor-related apoptosis-inducing ligand(TRAIL); triplex forming oligonucleotides (TFO); melanoma differentiation associated gene-7 (mda-7); carcinoembryonic antigen(CEA); replication-deficient adenovirus vector, Ad-mda7 (INGN 241); MAPK-activated kinases (Rsks); ). Insulin-like growth factorbinding proteins (IGFBPs); cyclooxygenase (COX)-2; ganglioside G(D2); Herpes simplex virus 1 (HSV); thymidine kinase (tk);ganciclovir (GCV); gastrin-releasing peptide (GRP); neuron specific enolase (NSE); Cre recombinase(Cre)/loxP; hypoxanthine-guaninephosphoribosyl transferase (HGPRT); Trypanosoma brucei (Tb); sodium iodide symporter (NIS); thyroperoxidase (TPO); matrixmetalloproteinase (MMP); secret form of human platelet facter 4 (Spf4); vascular endothelial growth factor (VEGF); soluble flt-1 (sFLT-1); Tie2-expressing mononuclear (TEM); dendritic cells (DCs); Lewis lung carcinoma (LLC); natural killer (NK) cells; tumor necrosisfactor receptor (TNF-R); 1,3) Galactosyl epitopes (·Gal); proliferin-related protein (PRP); interferon-inducible protein 10 (IP10);interferon (IFN)Received: 29 October 2003; Accepted: 1 December 2003;Revised: 23 December 2003; electronically published: December 2003SummaryLung cancer is the most lethal cancer worldwide. Although progress has been made in prevention, early detection,and treatment, mortality from this disease is still increasing. Current treatments in clinical trials have yielded onlyvery limited results, and it is therefore necessary to develop new therapeutic strategies. Gene therapy is a novel fieldof medicine that may signal a more promising future for patients with lung cancer. Several studies on lung cancertherapy have held out the promise of treatment methods, including the alteration of intracellular molecular defects,the introduction of suicide genes, the inhibition of angiogenesis, and the augmentation of specific antitumorimmunity. Various methods have been used to achieve specific gene transduction and effective gene expression.Clinical trials indicate that a combination of different treatment modalities is needed to obtain better results in lungcancer therapy. This review will summarize and discuss some recent advances and the potential future applicationsof gene therapy approaches in lung cancer.I. IntroductionLung cancer is the most common cause of death bycancer in both men and women, accounting for 18% of allcancer cases around the world. The average worldwideincidence of lung cancer is 37.5 per 100,000 persons,though this number varies greatly by country. Theincidence is highest in Eastern Europe and lowest inAfrica. The 5-year survival rate for lung cancer is 11%worldwide. In most countries, mortality from this diseaseis still increasing, especially in Southern and EasternEurope (Parkin et al, 1999). The American Cancer Societyestimates that 171,900 new cases of lung cancer will bediagnosed in the United States in 2003 alone. About157,200 people will die of this disease: 88,400 men and68,800 women, accounting for 28% of all cancer deaths.More people die of lung cancer than of colon, breast, andprostate cancers combined (Jemal et al, 2003).Lung cancer is divided into two main histologicgroups: small cell lung cancer (SCLC) and non-small celllung cancer (NSCLC). Approximately 80% of lung cancercases are NSCLC, with small cell lung cancer (SCLC)accounting for the remaining 20%. Lung cancer arisesfrom a series of morphological and molecular changes inwhich a normal epithelium transforms into an invasivecancer. To date, no efficient and safe therapy has yet beenintroduced for lung therapy.Gene therapy, although still a comparatively youngdiscipline, has made rapid strides in the past decade (Xu etal., 2003). Considerable efforts have been made toimprove protocols for human gene therapy. Four mainstrategies for the treatment of cancer have been reported:alteration of mutated genes; introduction of suicide genes;255
Page 7 and 8:
Instructions to authors:Gene Therap
Page 9:
Please submit an electronic version
Page 12:
103-111 ResearchArticle113-133 Revi
Page 17 and 18:
Gene Therapy and Molecular Biology
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77:
Page 80 and 81:
Epperly et al: Late injection of Mn
Page 82 and 83:
Epperly et al: Late injection of Mn
Page 84 and 85:
Goldberg-Cohen et al: Regulation of
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Gascón-Irún et al: Gene therapy a
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Suzuki et al: Regulation of the Sp/
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Li et al: MET amplification in live
Page 116 and 117:
Li et al: MET amplification in live
Page 118 and 119:
Chavakis et al: Leukocyte adhesion
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Sanlioglu et al: Adenovirus mediate
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
George et al: Gene therapy for vasc
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Zhang et al: Angiogenic Gene Therap
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Xu et al: G-CSF receptor-mediated S
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Burek et al: Calcium induced cell d
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
David et al: Current status and fut
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219: David et al: Current status and fut
Page 226 and 227: Stoll et al: The role of EBV and ge
Page 236 and 237: Maruyama et al: Kidney-targeted pla
Page 244 and 245: Kren et al: Hepatocyte-targeted del
Page 254 and 255: Zeng: PRL-3 as a target for cancer
Page 260 and 261: Latchman: Protective effect of heat
Page 270 and 271: Cai et al: Lung cancer gene therapy
Page 280: Cai et al: Lung cancer gene therapy
Page 283 and 284: Gene Therapy and Molecular Biology
Page 309: Gene Therapy and Molecular Biology
show all

GTMB 7 - Gene Therapy & Molecular Biology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?